Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA6 | P23280 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL11499605 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL11499604 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL3873614 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL5503172 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL22749381 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL23211676 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL11142512 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL11764117 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL21332424 | 0.95 | TSHR (0.67) | TSHRMEN1ALDH1A1KMT2ACA5A | |
| Sulfuric Acid SCHEMBL28438386 | 0.95 | TSHR (0.82) | TSHRMEN1ALDH1A1KMT2ACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105008364-B | substituted Imidazopyridazines | 拜耳制药股份公司 | 2017-11-07 | — | — | CN | disclosed |
| EP-2961752-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma AG (DE) | 2017-09-13 | — | — | EP | disclosed |
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-23 | — | — | US | disclosed |
| EP-3007698-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | Bayer Pharma Aktiengesellschaft (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | US | disclosed |
| EP-2961752-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Pharma Aktiengesellschaft (DE) | 2016-01-06 | — | — | EP | disclosed |
| CN-105008364-A | Substituted imidazopyridazines | Bayer Pharma AG | 2015-10-28 | — | — | CN | disclosed |
| US-9018417-B2 | Process for recovering aliphatic monocarboxylic acids from distillation | OXEA GMBH (DE) | 2015-04-28 | — | — | US | disclosed |
| WO-2015036844-A1 | COMPOSITIONS COMPRISING MEDIUM SUPERNATANT OF A STEM CELL CULTURE | BLUE HORIZON INTERNATIONAL LLC (US) | 2015-03-19 | — | — | WO | disclosed |
| EP-2848285-A1 | Compositions comprising medium supernatant of a stem cell culture | Blue Horizon International LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| WO-2014198776-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-12-18 | — | — | WO | disclosed |
| US-20140303401-A1 | Process for Recovering Aliphatic Monocarboxylic Acids from Distillation Residues | OQ CHEMICALS GMBH (DE) | 2014-10-09 | — | — | US | disclosed |
| WO-2014131739-A2 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014020041-A1 | COMBINATIONS FOR THE TREATMENT OF CANCER | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-02-06 | — | — | WO | disclosed |
| US-5977074-A | THERAPY FOR ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5166394-A | Reaction of tetramethylurea and oxalyl chloride for salt formation | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-11-24 | — | — | US | disclosed |
| US-4630963-A | RAPID GELATION | WYMAN RANSOME J | 1986-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175306-A1 | COMBINATION OF A IMIDAZOPYRIDAZINE DERIVATIVE AND A MITOTIC AGENT FOR THE TREATMENT OF CANCER | BUB1, BUB1B, CDK1 | TSHR 3185/4885MEN1 452/4885ALDH1A1 3808/4885 |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, PGF, VHL | TSHR 4033/4885MEN1 2333/4885ALDH1A1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.